Successful A2 to B Deceased Donor Kidney Transplant after Desensitization for High-Strength Non-HLA Antibody Made Possible by Utilizing a Hepatitis C Positive Donor.

Case Reports in Transplantation Pub Date : 2020-03-13 eCollection Date: 2020-01-01 DOI:10.1155/2020/3591274
H Charli Karpel, Nicole M Ali, Nikki Lawson, Vasishta S Tatapudi, Rex Friedlander, Mary Carmelle Philogene, Robert A Montgomery, Bonnie E Lonze
{"title":"Successful A2 to B Deceased Donor Kidney Transplant after Desensitization for High-Strength Non-HLA Antibody Made Possible by Utilizing a Hepatitis C Positive Donor.","authors":"H Charli Karpel,&nbsp;Nicole M Ali,&nbsp;Nikki Lawson,&nbsp;Vasishta S Tatapudi,&nbsp;Rex Friedlander,&nbsp;Mary Carmelle Philogene,&nbsp;Robert A Montgomery,&nbsp;Bonnie E Lonze","doi":"10.1155/2020/3591274","DOIUrl":null,"url":null,"abstract":"<p><p>Desensitization using plasma exchange can remove harmful antibodies prior to transplantation and mitigate risks for hyperacute and severe early acute antibody-mediated rejection. Traditionally, the use of plasma exchange requires a living donor so that the timing of treatments relative to transplant can be planned. Non-HLA antibody is increasingly recognized as capable of causing antibody-mediated renal allograft rejection and has been associated with decreased graft longevity. Our patient had high-strength non-HLA antibody deemed prohibitive to transplantation without desensitization, but no living donors. As the patient was eligible to receive an A2 ABO blood group organ and was willing to accept a hepatitis C positive donor kidney, this afforded a high probability of receiving an offer within a short enough time frame to attempt empiric desensitization in anticipation of a deceased donor transplant. Fifteen plasma exchange treatments were performed before the patient received an organ offer, and the patient was successfully transplanted. Hepatitis C infection was treated posttransplant. No episodes of rejection were observed. At one-year posttransplant, the patient maintains good graft function. In this case, willingness to consider nontraditional donor organs enabled us to mimic living donor desensitization using a deceased donor.</p>","PeriodicalId":30327,"journal":{"name":"Case Reports in Transplantation","volume":"2020 ","pages":"3591274"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/3591274","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/3591274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Desensitization using plasma exchange can remove harmful antibodies prior to transplantation and mitigate risks for hyperacute and severe early acute antibody-mediated rejection. Traditionally, the use of plasma exchange requires a living donor so that the timing of treatments relative to transplant can be planned. Non-HLA antibody is increasingly recognized as capable of causing antibody-mediated renal allograft rejection and has been associated with decreased graft longevity. Our patient had high-strength non-HLA antibody deemed prohibitive to transplantation without desensitization, but no living donors. As the patient was eligible to receive an A2 ABO blood group organ and was willing to accept a hepatitis C positive donor kidney, this afforded a high probability of receiving an offer within a short enough time frame to attempt empiric desensitization in anticipation of a deceased donor transplant. Fifteen plasma exchange treatments were performed before the patient received an organ offer, and the patient was successfully transplanted. Hepatitis C infection was treated posttransplant. No episodes of rejection were observed. At one-year posttransplant, the patient maintains good graft function. In this case, willingness to consider nontraditional donor organs enabled us to mimic living donor desensitization using a deceased donor.

Abstract Image

通过使用丙型肝炎阳性供体,高强度非hla抗体脱敏后成功进行A2到B的已故供体肾移植。
血浆置换脱敏可以在移植前清除有害抗体,降低超急性和严重早期急性抗体介导的排斥反应的风险。传统上,使用血浆交换需要一个活体供体,以便可以计划相对于移植的治疗时间。非hla抗体越来越多地被认为能够引起抗体介导的肾移植排斥反应,并与移植物寿命缩短有关。我们的患者有高强度的非hla抗体,认为不脱敏的移植是禁止的,但没有活体供体。由于患者有资格接受A2 ABO血型器官,并且愿意接受丙型肝炎阳性供体肾脏,这就提供了在足够短的时间内接受供体提供的高概率,以便在预期已故供体移植时尝试经验性脱敏。在患者接受器官捐献之前,进行了15次血浆交换治疗,患者移植成功。移植后治疗丙型肝炎感染。未观察到排斥反应。移植后一年,患者保持良好的移植物功能。在这种情况下,考虑非传统供体器官的意愿使我们能够使用已故供体来模拟活体供体的脱敏。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信